• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell, Marginal Zone - 24 Studies Found

Not yet recruiting : Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma
: Splenic Marginal Zone Lymphoma
: 2016-10-23
Not yet recruiting : Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
: MALT Lymphoma
: 2009-06-17
: Drug: Lenalidomide 25 mg Lenalidomide p.o. daily for 21 days
Completed : Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
: MALT Lymphoma
: 2006-09-07
: Drug: Thalidomide, Pharmion 200 mg p.o. daily
Active, not recruiting : R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)
: Lymphoma
: 2011-08-30
: Drug: rituximab, cyclophosphamide, vincristine, and prednisolone 6 cycles of R-CVP followed by 2 cycles
<<< Previous
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.